New aspects in the pathogenesis of dialysis-related amyloidosis: Pathophysiology of advanced glycation end products in renal failure

Japanese Journal of Nephrology

Volumn 38, Issue 5, 1996, Pages 191-197

  Miyata, Toshio ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

2 microglobulin; Advanced glycation end products; Dialysis related amyloidosis; Glycoxidation; Redox imbalance

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BETA 2 MICROGLOBULIN;

AMYLOIDOSIS; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW;

AMYLOIDOSIS; BETA 2-MICROGLOBULIN; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 3142588980     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Koch KM: Dialysis-related amyloidosis. Kidney Int. 41: 1416-1429, 1992
2. Miyata T, Maeda K: Pathogenesis of dialysis-related amyloidosis. Cur Opt Nephrol Hyperten 4: 493-497, 1995
3. van Yperscle de Strihou C, Jadoul M, Malghem J, Maldegue B, Jamart J: Effect of dialysis membrane and patient's age on signs of DRA. Kidney Int 39: 1012-1019, 1991
4. Ohashi K, Kara M, Kawai R, Ogura Y, Honda K, Nihci H, Mimura N: Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41: 1646-1652, 1992
5. Argilés A, Mourad G, Kerr PG, Garcia M, Collins B, Demaille JG: Cells surrounding haemodialysis-associated amyloid deposits arc mainly macrophages. Nephrol Dial Transplant 9: 662-667, 1994
6. Geyjo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen AS, Schmid K: A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129: 701-706, 1985
7. Gorevic PD, Munoz PC, Casey TT, DiRaimondo CR, Stone WJ, Prelli FC, Rodrigues MM, Poulik MD, Frangione B: Polymerization of intact β2 microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci USA 83: 7908-7912, 1986
8. Linke RP, Hampl H, Lobeck H, Ritz E, Bommer J, Waldherr R, Eulitz M: Lysine-specific cleavage of β2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36: 675-681, 1989
9. Odani H, Oyama R, Titani K, Ogawa H, Saito A: Purification and complete amino acid sequence of nove β2-microglobulin. Biochem Biophys Res Commun 168: 1223-1229, 1990
10. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Tamguchi N, Maeda K, Kinoshita T: β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92: 1243-1252, 1993
11. Ogawa H, Saito A, Oda O, Nakajima M, Chung TG: Detection of novel β2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 30: 158-163, 1988
12. Miyata T, Taneda S, Kawa R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-contaming amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 93: 2353-2358, 1996
13. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988
14. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992
15. Miyata T, Inagi R, Wada Y, Ueda Y, Iida Y, Takahashi M, Taniguchi N, Maeda K: Glycation of human β2-microglobulin in patients with hemodialysis-associated amyloidosis: Identification of the glycated sites. Biochemistry 33: 12215-12221, 1994
16. Miyata T, Iida Y, Ueda Y, Shinzato T, Seo H, Monnier VM, Maeda K, Wada Y: Monocyte/macrophage response to β2-microglobulin modified with the advanced glycation end products. Kidney Int 49: 538-550, 1996
17. Miyata T, Kawai R, Taneda S, Hara M, Monnier VM, Maeda K: Identification of the native structures for advanced glycation end products in β2-microglobulin containing amyloid fibrils in patients with dialysis-related amyloidosis. (abstract) J Amer Soc Nephrol 6: 552, 1995
18. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264: 21597-21602, 1989
19. epsi;-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878, 1995
20. epsi;-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 889-4894, 1986
21. epsi;-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 29: 10964-10970, 1990
22. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formation of pentosidine during nonenzymatic browning of protein by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266: 11654-11660, 1991
23. Baynes JW: Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991
24. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87: 9010-9014, 1990
25. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNS and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 240: 1546-1548, 1988
26. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda M, Seo H: Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J Clin Invest 93: 521-528, 1994
27. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K: β2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 201: 1235-1241, 1994
28. Schmidt AM, Yon SD, Brett J, Mora R, Nowygrod R, Stern D: Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 92: 2155-2168, 1993
29. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897, 1994
30. Yan SD, Yan FF, Chen X, Jin F, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier JL, Stern D: Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nature Med 1: 693-699, 1995
31. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174: 931-939, 1991
32. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89: 2873-2877, 1992
33. Nagaraj RH, Sell DR, Prabhahkaram M, Ortwerth BJ, Monnier VM: High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. Proc Natl Acad Sci USA 88: 10257-10261, 1991
34. Iida Y, Miyata T, Maeda K, Hori O, Stern D, Schmidt AM, Monocyte/macrophage interaction of nonenzymatically glycated β2-microglobulin is mediated by the receptor for advanced glycation end products: Role in the pathogenesis of dialysis-related amyloidosis. (abstract) J Amer Soc Nephrol 6: 536, 1995
35. Miyata T, Notoya K, Iida Y, Taketomi S, Tsuda M, Maeda K: β2-Microglobulin modified with advanced glycation end products enhances osteoclastic bone resorption: Role in the pathogenesis of dialysis-related amyloidosis. (abstract) J Amer Soc Nephrol 6: 532, 1995
36. Odetti P, Forgarty J, Sell DR, Monnier VM: Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41: 153-159, 1992
37. Beisswenger PJ, Moore LL, Brink-Johnsen T: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92: 212-217, 1993
38. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993
39. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM: Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 41: 1286-1292, 1992
40. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2748, 1993
41. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991
42. Sell DR, Monier VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85: 380-384, 1990
43. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Preopuolos D, Diamandis EP: Immunological quantification of advanced glycosylation endproducts in the serum of patients on hemodialysis or CAPD. Kidney Int 46: 216-222, 1994
44. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, van Yperesle de Strihou, Maeda K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol (in press)
45. Bucala R, Makita Z, Vega G, Grundy S, Kuschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91: 9441-9445, 1994
46. epsi;-lysino)-lactic acid from model compounds and glycated proteins. J Biol Chem 263: 8816-8821, 1988
47. Loughrey CM, Young IS, Kightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. Q J Med 87: 679-683, 1994
48. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radie Biol Med 16: 339-346, 1994
49. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P, Pascucci M, Bossu M: Erythrocyte redox state in uremic anemia: Effects of hemodialysis and relevance of glutathione metabolism, Acta Haematol 91: 187-193, 1994
50. Wolff SP, Dean RT: Glucose autoxidation and protein modification: The potential role of autoxidative glycosylation in diabetes. Biochem J 245: 243-250, 1987
51. Hunt JV, Dean RT, Wolff SP: Hydroxyl radical production and autoxidative glycosylation: Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and aging. Biochem J 256: 205-212, 1988